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Abstract
Hop/STI1 (Hsp-organizing protein/stress-induced-phosphoprotein 1) is a molecular cochaperone, which coordinates Hsp70 and Hsp90 activity during client protein folding
through interactions with its TPR1 and TPR2A domains. Hsp90 substrates include a
diverse set of proteins, many of which have been implicated in tumorogenesis. Overexpression of Hsp90 in cancer cells stabilizes mutant oncoproteins promoting cancer cell
survival. Disruption of Hsp90 and its co-chaperone machinery has become a promising
strategy for the treatment of cancer. STI1 has also been described as a neurotrophic
signaling molecule through its interactions with the prion protein (PrPC). Here, we report
the 1H, 13C and 15N backbone assignments of the TPR1 and TPR2A domains of mouse
STI1, which interact with Hsp70 and Hsp90, respectively. 1H-15N HSQC spectra of
TPR2A domain in the presence of a peptide encoding the C-terminal Hsp90 binding site
revealed significant chemical shift changes indicating complex formation. These results
will facilitate the screening of potential molecules that inhibit STI1 complex formation
with Hsp70 and/or Hsp90 for the treatment of cancer and detailed structural studies of the
STI1-PrPC complex.
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Biological context
Heat-shock protein (Hsp)70 and Hsp90 are chaperones which mediate folding of
key cellular client proteins involved in processes such as proliferation, differentiation and
apoptosis (Taipale et al. 2010; Young et al. 2004). Hsp90 targets numerous proteins
implicated in tumor growth and survival including steroid hormone receptors and protooncogenic kinases such as Akt (Sato et al. 2000), Raf-1 (Stancato et al. 1993) and
Her2/neu (Xu et al. 2001). Hsp90 over-expression correlates with tumor invasiveness and
poor prognosis, thus pharmacological inhibition of the chaperone response has become an
alluring target for therapeutic intervention in multiple cancer types (Trepel et al. 2010).
Client maturation is facilitated by a number of co-chaperone proteins that regulate
Hsp70 and Hsp90 activity. Hop/STI1 (Hsp-organizing protein/stress-inducedphosphoprotein 1) is a key scaffold protein, which mediates client transfer from Hsp70 to
Hsp90 in the later stages of client maturation (Smith et al. 1993; Chen and Smith 1998).
Initially, client proteins complex with Hsp40 and Hsp70 (Hernandez et al. 2002; Pratt and
Toft 2003). Then Hop/STI1 promotes client transfer from Hsp70 to Hsp90 by
simultaneously binding the two chaperones through distinct tetracopeptide repeat (TPR)
domains (Scheufler et al. 2000).
Hop/STI1 encodes three TPR domains, TPR1, TPR2A and TPR2B and two
aspartate-proline motif regions (DP1 and DP2) (Odunuga et al. 2003). TPR domains are
composed of multiple degenerate 34 amino acid repeats forming anti-parallel helix-turnhelix motifs. These serve as protein-protein interaction modules in multi-protein
complexes (Cortajarena and Regan 2006). TPR1 and TPR2A preferentially bind the
conserved C-terminal residue ‘EEVD’ motifs of Hsp70 and Hsp90, respectively. X-ray
crystallographic data of human TPR1 and TPR2A domain in complex with Hsp70 and
Hsp90 C-terminal peptides indicate specificity is determined by hydrophobic contacts
directly N-terminal of the ‘EEVD’ motif (Scheufler et al. 2000).
Studies have demonstrated that STI1 promotes proliferation and migration in
glioblastoma and pancreatic cancer cell lines (Fonseca et al. 2012; Walsh et al. 2011).
Down-regulation of STI1 by RNAi resulted in decreased pancreatic cell line invasiveness
and down-regulation of numerous oncogenic Hsp90 client proteins (Walsh et al. 2011).
Inhibition of Hsp90 interaction with the TPR2A domain of STI1 using a novel hybrid
TPR peptide has demonstrated selective cancer-cell cytotoxicity (Horibe et al. 2011).
Secreted STI1 also functions as a cell-signaling molecule promoting neuritogenesis and
neuroprotection to hippocampal neurons through its interaction with the cellular prion
protein (PrPC) (Zanata et al. 2002; Lopes et al. 2005). The PrPC binding site of STI1 has
been localized to the TPR2A domain of STI1. The neurotrophic signaling induced by
PrPC-STI1 binding may have a role in the pathology of neurodegenerative diseases.
Backbone resonance assignment of the TPR1 and TPR2A domains will facilitate
screening of further selective inhibitors of Hsp complex formation that may prove
effective in cancer treatment and for future studies involving the STI1-PrPC signaling
complex.

Methods and experiments
Plasmid generations
The expression vector pTrcHis containing mouse STI1 cDNA (GenBank# NM_016737)
was graciously provided by Dr. Vilma Martins (A.C. Camargo Hospital, Sao Paulo,
Brazil). Sequence encoding the TPR1 domain, residues 2-118, were amplified by PCR
using the two primers:
5’-GGGGACAAGTTTGTACAAAAAAGCAGGCTCTGAAAACCTGTATTTTCAGG
GAGAGCAGGTGAATGAGCTAAAGG-3’ and
5’-GGGGACCACTTTGTACAAGAAAGCTGGGTCTCACCTGGCCTCCATGTTCT
G-3’.
TPR2A domain, residues 217-352, were amplified by two successive rounds of PCR
using primers 5’-GAAAACCTGTATTTTCAGGGAGATCTTCCAGAGAATAA-3’ and
5’-AAGAAAGCTGGGTCTCACAAGCGCTCCTG-3’ followed by amplification using
5’-GGGGACAAGTTTGTACAAAAAAGCAGGCTCTGAAAACCTGTATTTTC-3’
and 5’-GGGGACCACTTTGTACAAGAAAGCTGGG-3’. The resultant cDNA was
cloned into separate pDEST17 (Invitrogen) expression vectors with an additional tobacco
etch virus (TEV) cleavage recognition site ‘ENLYFQG’ between the 6xHis tag and the
insert.
Sample preparation
The expression vectors containing mouse TPR1 and TPR2A were transformed in E. coli
BL21 (DE3) pLysS. Uniformly 15N, 13C- labeled protein was over-expressed by growing
E. coli in 1 L M9 media supplemented with 1 g of NH4Cl and 3 g of 13C-glucose at 37°C
to an OD600 of 0.9, at which point protein over-expression was induced with 1 mM IPTG.
Cultures grew for 6 hours at 37 °C and centrifuged pellets were frozen. N-terminally Histagged fusion proteins were purified by affinity chromatography using Ni SepharoseTM 6
Fast Flow beads (Amersham Biosciences). The N-terminal His-tag was removed by
incubation with His-tagged TEV protease overnight at 22 °C. TEV protease was removed
by an additional affinity chromatography step using Ni SepharoseTM 6 Fast Flow beads
(Amersham Biosciences). Proteins were dialyzed into 50 mM sodium phosphate buffer,
50 mM NaCl, 1mM DTT at pH 7 and subsequently concentrated to ~ 500 µM. NMR
samples contained 10 % D2O and 100 µM 2,2-dimethyl-2-sila-pentane-5-sulfonic acid
(DSS) for 1H and 13C chemical shift referencing.
NMR spectroscopy
NMR experiments for backbone resonance assignments of TPR1 and TPR2A were
conducted at 25°C on a Varian INOVA 600 MHz spectrometer equipped with either a
cryogenic probe or a regular triple resonance probe (UWO Biomolecular NMR Facility).
Sequential assignments were obtained for the TPR1 domain using the following
experiments: HNCACB and CBCA(CO)NH and C(CO)NH spectra. The TPR2A domain
was assigned using HNCACB and CBCA(CO)NH experiments. All spectra were

processed using NMRPipe (Delaglio et al. 1995) and analyzed using CARA (Keller
2004).
Ligand Binding experiment
Binding of the TPR2A domain to the peptide encoding the C-terminal Hsp90 residues
(Ac-MEEVD-NH2 ordered from GenScript Inc. USA) was confirmed by 1H-15N HSQC
spectra collected in the presence and absence of equimolar concentrations of Hsp90
peptide (~250 µM). Experiments were collected on a Varian INOVA 600 MHz
spectrometer equipped with a cryogenic probe (UWO Biomolecular NMR Facility).
Assignments and data deposition
Backbone resonance assignments for 1HN, 15N, 13Cα and 13Cβ were obtained for the
TPR1 and TPR2A domains of STI1. For the TPR1 domain, 97% of the 1HN and 15N
resonances of non-proline residues, 94% 13Cα and 87% 13Cβ of all residues were
assigned (Fig. 1). For the TPR2A domain, 99% of 1HN and 15N resonances of non-proline
residues, 95% 13Cα and 96% 13Cβ of all residues were assigned (Fig. 2). Chemical shift
assignments have been deposited in the BioMagResBank (http://www.bmrb.wisc.edu),
under accession numbers 18691 and 18689 for the TPR1 and TPR2A domains,
respectively.
Crystal structures of TPR1 and TPR2A in complex with C-terminal peptides of
Hsp70 and Hsp90 indicate each domain to be composed of seven α-helices arranged in
anti-parallel helix-turn-helix motifs (Scheufler et al. 2000) (PDB: 1ELW for TPR1 and
PDB: 1ELR for TPR2A). Secondary structure propensity (SSP) scores (Marsh et al.
2006) using 13C α/β chemical shifts indicate no β-strand propensity in TPR1 or TPR2A
domains and agree with the secondary structure diagram (Laskowski 2009) generated
from the TPR1 and TPR2A crystal structures (Fig. 3) (Scheufler et al. 2000).
1
H-15N HSQC of the TPR2A domain collected in the absence and presence of
equimolar concentrations of Hsp90 C-terminal peptide produced large chemical shift
changes indicative of binding (Fig. 4a). The magnitude of chemical shift perturbations for
traceable residues was calculated from the combined chemical shift changes in 1H and
15
N dimensions (Δω = |0.2 * Δ15N| + |Δ1HN|) in ppm. Residues demonstrating the largest
combined chemical shift changes (> 0.1 ppm) clustered to the binding interface of the
TPR2A-Hsp90 C-terminal peptide complex (Fig. 4b) (Scheufler et al. 2000) further
confirming the assignment.
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Figure Legends
Fig. 1 a 1H-15N HSQC spectrum and backbone resonance assignment of 15N/13C labeled
TPR1 domain of STI1. Spectra were generated using Sparky (Goddard and Kneller). b
Amino acid sequence of TPR1 domain with unassigned residues colored red. The Nterminal glycine is a non-native residue from the TEV protease recognition site.
Fig. 2 a 1H-15N HSQC spectrum and backbone resonance assignment of 15N/13C labeled
TPR2A domain of STI1. Spectra were generated using Sparky (Goddard and Kneller). b
Amino acid sequence of TPR2A domain with unassigned residues colored red. The Nterminal glycine is a non-native residue from the TEV protease recognition site.
Fig. 3 Secondary structure propensity (SSP) scores and DSSP analysis of a the TPR1 and
b TPR2A domains of STI1. 13C α/β chemical shifts were used to calculate SSP scores for
each domain (Marsh et al. 2006). Crystal structures of TPR1 in complex with Hsp70 Cterminal peptide (PDB: 1ELW) and TPR2A in complex with C-terminal Hsp90 peptide
(PDB: 1ELR) (Scheufler et al. 2000) were used to generate the secondary structure
diagrams of each domain (Laskowski 2009).
Fig. 4 a Overlay of 1H-15N HSQC spectra of TPR2A in the absence (black) and presence
(red) of equimolar concentrations of Hsp90 C-terminal peptide. b Crystal structure of
TPR2A in complex with Hsp90 peptide (PDB: 1ELR; Scheufler et al. 2000) with
traceable chemical shift changes upon addition of Hsp90 peptide colored based on the
magnitude of the combined chemical shift changes in 1H and 15N dimensions.
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